دورية أكاديمية
أعرض في EDS

Unbiased chemokine receptor screening reveals similar efficacy of lymph node- and tumor-targeted T cell immunotherapy.

التفاصيل البيبلوغرافية
العنوان: Unbiased chemokine receptor screening reveals similar efficacy of lymph node- and tumor-targeted T cell immunotherapy.
المؤلفون: Pachmayr LO; Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine, Technical University of Munich (TUM), Munich, Germany., Muehlbauer A; Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine, Technical University of Munich (TUM), Munich, Germany., Flommersfeld S; Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine, Technical University of Munich (TUM), Munich, Germany., Graml F; Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine, Technical University of Munich (TUM), Munich, Germany., Hoenninger J; Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine, Technical University of Munich (TUM), Munich, Germany., von Baumgarten L; Department of Neurosurgery, Ludwigs-Maximilians-University (LMU), Munich, Germany., Buchholz VR; Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine, Technical University of Munich (TUM), Munich, Germany. veit.buchholz@tum.de., Grassmann S; Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine, Technical University of Munich (TUM), Munich, Germany. grassmaS@mskcc.org.; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. grassmaS@mskcc.org.
المصدر: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2023 Sep; Vol. 72 (9), pp. 3111-3124. Date of Electronic Publication: 2023 Jun 10.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
أسماء مطبوعة: Publication: Berlin : Springer Verlag
Original Publication: Berlin ; New York, NY : Springer International, c1982-
مواضيع طبية MeSH: CD8-Positive T-Lymphocytes* , Skin Neoplasms*/pathology, Humans ; Mice ; Animals ; Receptors, Chemokine ; Immunotherapy ; Lymph Nodes ; Immunotherapy, Adoptive ; Mice, Inbred C57BL
مستخلص: Localization is a crucial prerequisite for immune cell function and solid tumors evade immune control by modulating immune cell infiltration into the tumor stroma. Immunosuppressive cells like regulatory T cells are attracted, while cytotoxic CD8 + T cells are excluded. Engineering CD8 + T cells with chemokine receptors is a potent strategy to turn this mechanism of directed immune cell recruitment against the tumor. Here, we utilized fluorescent tagging to track the migratory behavior of tumor-specific T cells engineered with a library of all murine chemokine receptors in vivo. We then asked whether chemokine receptor-mediated redirection of antigen-specific T cells into tumors or tumor-draining lymph nodes showed superior anti-tumoral activity. We found that both targeting approaches showed higher therapeutic efficacy than control T cells. However, multiple receptors conveying the same homing pattern did not augment infiltration. Instead, in the MC38 colon carcinoma model, anti-tumoral efficacy as well as lymph node vs. tumor-homing patterns were mostly driven by CCR4 and CCR6, respectively. Overall, our data, based on fluorescent receptor tagging, identify the tumor-draining lymph node and the tumor itself as viable targets for chemokine receptor-mediated enhancement of adoptive T cell therapy.
(© 2023. The Author(s).)
References: Nat Biomed Eng. 2021 Nov;5(11):1246-1260. (PMID: 34083764)
Int J Mol Sci. 2020 Jul 22;21(15):. (PMID: 32707869)
J Immunother Cancer. 2016 Apr 19;4:21. (PMID: 27096098)
Cancer Res. 2015 Nov 1;75(21):4483-93. (PMID: 26432403)
Sci Bull (Beijing). 2021 Apr 30;66(8):803-812. (PMID: 36654137)
Nature. 2014 Nov 6;515(7525):130-3. (PMID: 25337873)
Nature. 2016 Sep 15;537(7620):417-421. (PMID: 27501248)
Nature. 2022 Sep;609(7926):354-360. (PMID: 35978192)
Immunity. 2012 Dec 14;37(6):1091-103. (PMID: 23123063)
Int J Oncol. 2008 Aug;33(2):297-308. (PMID: 18636150)
J Immunol. 2009 Jun 1;182(11):6682-9. (PMID: 19454662)
Sci Immunol. 2021 Oct;6(64):eabg7836. (PMID: 34597124)
J Biol Chem. 2012 Oct 19;287(43):36593-608. (PMID: 22927430)
Cell Mol Immunol. 2018 Apr;15(4):324-334. (PMID: 29375126)
Cancer Res. 2009 Apr 1;69(7):3077-85. (PMID: 19293190)
Nat Immunol. 2020 Oct;21(10):1256-1266. (PMID: 32839610)
Nat Biomed Eng. 2019 Dec;3(12):974-984. (PMID: 31182835)
Int J Mol Sci. 2023 Mar 12;24(6):. (PMID: 36982500)
J Exp Med. 2019 May 6;216(5):1170-1181. (PMID: 30910796)
J Exp Med. 2023 Jun 5;220(6):. (PMID: 36946983)
J Immunol. 2003 Mar 15;170(6):3369-76. (PMID: 12626597)
Nat Immunol. 2007 Nov;8(11):1255-65. (PMID: 17893676)
Nat Immunol. 2020 Dec;21(12):1563-1573. (PMID: 33106669)
Nature. 2017 Mar 2;543(7643):113-117. (PMID: 28225754)
Immunity. 2021 Oct 12;54(10):2288-2304.e7. (PMID: 34437840)
Cancer Res. 2009 Feb 15;69(4):1587-95. (PMID: 19190335)
Clin Cancer Res. 2011 Jul 15;17(14):4719-30. (PMID: 21610146)
Clin Cancer Res. 2010 Nov 15;16(22):5458-68. (PMID: 20889916)
Nature. 2011 Jul 13;475(7355):226-30. (PMID: 21753853)
Immun Inflamm Dis. 2021 Dec;9(4):1686-1695. (PMID: 34525267)
J Exp Med. 2014 Mar 10;211(3):515-27. (PMID: 24590765)
Nat Med. 2004 Sep;10(9):942-9. (PMID: 15322536)
Cancer Res. 2016 Oct 1;76(19):5671-5682. (PMID: 27530322)
Immunity. 2019 Jun 18;50(6):1498-1512.e5. (PMID: 31097342)
Oncoimmunology. 2015 Oct 29;5(3):e1105428. (PMID: 27195186)
Immunity. 2019 Jun 18;50(6):1391-1400.e4. (PMID: 31103380)
Nat Rev Immunol. 2017 Sep;17(9):559-572. (PMID: 28555670)
J Immunol. 2012 Dec 15;189(12):5602-11. (PMID: 23152559)
معلومات مُعتمدة: SFB-TRR 338/1 2021-452881907 Deutsche Forschungsgemeinschaft; SFB 1054 210592381 Deutsche Forschungsgemeinschaft; 70113918 Deutsche Krebshilfe
فهرسة مساهمة: Keywords: Adoptive T cell therapy; Cancer immunotherapy; Chemokine receptors; Solid tumors; Tumor homing
المشرفين على المادة: 0 (Receptors, Chemokine)
تواريخ الأحداث: Date Created: 20230610 Date Completed: 20230811 Latest Revision: 20230812
رمز التحديث: 20230812
مُعرف محوري في PubMed: PMC10412482
DOI: 10.1007/s00262-023-03472-w
PMID: 37301772
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-0851
DOI:10.1007/s00262-023-03472-w